[go: up one dir, main page]

TN2009000387A1 - Use of a masked or coated copper salt for the treatment of macular degeneration - Google Patents

Use of a masked or coated copper salt for the treatment of macular degeneration

Info

Publication number
TN2009000387A1
TN2009000387A1 TNP2009000387A TN2009000387A TN2009000387A1 TN 2009000387 A1 TN2009000387 A1 TN 2009000387A1 TN P2009000387 A TNP2009000387 A TN P2009000387A TN 2009000387 A TN2009000387 A TN 2009000387A TN 2009000387 A1 TN2009000387 A1 TN 2009000387A1
Authority
TN
Tunisia
Prior art keywords
masked
treatment
copper salt
coated copper
macular degeneration
Prior art date
Application number
TNP2009000387A
Other languages
English (en)
Inventor
Georg Ludwig Kis
Jacques Vandermander
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39477329&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000387(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07104792A external-priority patent/EP1974733A1/fr
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TN2009000387A1 publication Critical patent/TN2009000387A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/34Copper; Compounds thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12Fatty acids or derivatives thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16Inorganic salts, minerals or trace elements
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23PSHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P20/00Coating of foodstuffs; Coatings therefor; Making laminated, multi-layered, stuffed or hollow foodstuffs
    • A23P20/10Coating with edible coatings, e.g. with oils or fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/30Copper compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
TNP2009000387A 2007-03-23 2009-09-22 Use of a masked or coated copper salt for the treatment of macular degeneration TN2009000387A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07104792A EP1974733A1 (fr) 2007-03-23 2007-03-23 Utilisation d' un sel de cuivre masqué ou enrobé pour le traitment de la dégénérescence maculaire
EP07111322 2007-06-28
PCT/EP2008/053283 WO2008116806A1 (fr) 2007-03-23 2008-03-19 Utilisation d'un sel de cuivre masqué ou enrobé pour le traitement d'une dégénérescence maculaire

Publications (1)

Publication Number Publication Date
TN2009000387A1 true TN2009000387A1 (en) 2010-12-31

Family

ID=39477329

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000387A TN2009000387A1 (en) 2007-03-23 2009-09-22 Use of a masked or coated copper salt for the treatment of macular degeneration

Country Status (26)

Country Link
US (1) US20080233182A1 (fr)
EP (1) EP2124973B1 (fr)
JP (1) JP2010521534A (fr)
KR (1) KR101688656B1 (fr)
AR (1) AR065791A1 (fr)
AU (1) AU2008231847B2 (fr)
BR (1) BRPI0809258B8 (fr)
CA (1) CA2681514C (fr)
CL (1) CL2008000804A1 (fr)
CO (1) CO6230993A2 (fr)
DK (1) DK2124973T3 (fr)
EC (1) ECSP099700A (fr)
ES (1) ES2542694T3 (fr)
GT (1) GT200900251A (fr)
IL (1) IL201109A (fr)
MA (1) MA31293B1 (fr)
MX (1) MX2009010244A (fr)
MY (1) MY164520A (fr)
NZ (1) NZ579852A (fr)
PE (1) PE20090186A1 (fr)
PL (1) PL2124973T3 (fr)
PT (1) PT2124973E (fr)
RU (1) RU2009139002A (fr)
TN (1) TN2009000387A1 (fr)
TW (1) TW200904456A (fr)
WO (1) WO2008116806A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2979118T3 (es) 2009-03-09 2024-09-24 Basf As Composiciones que comprenden una mezcla de aceites de ácidos grasos y un ácido graso libre, y procedimientos y usos de las mismas
KR101759255B1 (ko) 2015-09-18 2017-07-18 한국산업기술대학교산학협력단 무촉매 방식 가변경사각을 갖는 나노 구조물 성장 방법
AR118962A1 (es) * 2019-05-22 2021-11-10 Bayer Consumer Care Ag Preparaciones de cápsulas de gelatina blanda de vitaminas y minerales que comprenden vitamina c en forma de una sal de ascorbato

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2043487A1 (fr) * 1969-05-28 1971-02-19 Commissariat Energie Atomique
US5298237A (en) * 1992-01-24 1994-03-29 The Trustees Of Columbia University In The City Of New York Gel composition for reduction of gingival inflammation and retardation of dental plaque
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
US20030004043A1 (en) * 2001-06-27 2003-01-02 Deola James A. Pivoting backrest for exercise apparatus
US20030104043A1 (en) * 2001-12-03 2003-06-05 Brown Beverly Ann Topical cream for alleviating spider veins
US20050249820A1 (en) * 2004-05-04 2005-11-10 Akorn, Inc. Nutritional supplement for the treatment and prevention of macular degeneration
WO2005110375A1 (fr) * 2004-05-08 2005-11-24 Paul Edward L Jr Supplément alimentaire pour le traitement des maladies oculaires
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
NZ552451A (en) * 2004-07-09 2010-07-30 Robert Sabin Compositions and methods of use for treatment of mammalian diseases
AU2005306320B2 (en) * 2004-11-19 2011-09-08 Martek Biosciences Corporation Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same

Also Published As

Publication number Publication date
CA2681514A1 (fr) 2008-10-02
JP2010521534A (ja) 2010-06-24
CO6230993A2 (es) 2010-12-20
EP2124973A1 (fr) 2009-12-02
CL2008000804A1 (es) 2008-10-24
MX2009010244A (es) 2009-10-26
MA31293B1 (fr) 2010-04-01
KR20100015799A (ko) 2010-02-12
MY164520A (en) 2017-12-29
RU2009139002A (ru) 2011-04-27
GT200900251A (es) 2018-10-08
PT2124973E (pt) 2015-09-01
AR065791A1 (es) 2009-07-01
DK2124973T3 (da) 2015-06-22
EP2124973B1 (fr) 2015-05-27
NZ579852A (en) 2012-03-30
BRPI0809258B8 (pt) 2021-05-25
BRPI0809258B1 (pt) 2019-10-01
US20080233182A1 (en) 2008-09-25
IL201109A0 (en) 2010-05-17
WO2008116806A1 (fr) 2008-10-02
KR101688656B1 (ko) 2016-12-21
PL2124973T3 (pl) 2015-10-30
TW200904456A (en) 2009-02-01
CA2681514C (fr) 2016-11-08
ES2542694T3 (es) 2015-08-10
ECSP099700A (es) 2009-11-30
IL201109A (en) 2016-10-31
AU2008231847B2 (en) 2012-12-06
PE20090186A1 (es) 2009-03-20
AU2008231847A1 (en) 2008-10-02
BRPI0809258A2 (pt) 2014-09-23

Similar Documents

Publication Publication Date Title
MX2009007075A (es) Metodos de uso para analogos de ciclopamina.
PT1888541E (pt) Compostos de benzo(d)isoxazol-3-il-amina substituídos como analgésicos
MY148253A (en) Azaadamantane derivatives and methods of use
MX2013011589A (es) Metodos y composiciones para tratar enfermedad de parkinson.
MY179607A (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
MY184303A (en) Notch pathway signaling inhibitor compound
EA201490269A1 (ru) Новое производное 1,2,3,4-тетрагидрохинолина, подходящее для лечения диабета
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
WO2010027424A3 (fr) Derives de tylophorine a base de phenanthrene substitues en 9
MX2013011333A (es) Combinaciones de compuestos inhibidores de akt y mek, y metodos de uso.
WO2009129497A3 (fr) Methodes et compositions de traitement de la degenerescence maculaire liee a l’age et d’identification de composes appropries
PL412210A1 (pl) Silnie fluorescencyjne substancje heterocykliczne i sposób ich syntezy
WO2008131946A3 (fr) Dérivés d'amide substitués
MX359363B (es) Dihidroetorfina y su preparacion.
MX2009004983A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.
MX2008011576A (es) Compuestos de imidazo[2,1-b]tiazol sustituidos y su uso para la produccion de farmacos.
TN2009000387A1 (en) Use of a masked or coated copper salt for the treatment of macular degeneration
WO2009125975A3 (fr) Combinaison de mitiglinide et de metformine et procédé de préparation de la combinaison
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
EP2062901A4 (fr) Composé de fluorobore ayant un noyau aromatique ou sel de celui-ci, et procédé de fabrication du composé ayant un noyau aromatique fusionné à un éther cyclique à l'aide de celui-ci
WO2007021711A3 (fr) Derives de 3-sulfonylindazole substitues en tant que ligands de 5-hydroxytryptamine-6
MX2008002158A (es) Derivados de azinil-3-sulfonilindazol como ligandos de 5-hidroxitriptamina-6.
MX2008012824A (es) Derivados de sulfonil-3-heterociclilindazol como ligandos de 5-hidroxitriptamina-6.
IN2015DN03243A (fr)